Elizabeth Sharlow
CEO
KeViRx, Inc.
I'm working on
3 months ago
Novel drugs targeting microvascular leakage and inflammation
I'm looking for
3 months ago
Partnerships, investment, co-development opportunities
About
KVX-053 is a new drug that repairs the damaged endothelial lining within blood vessels after an injury. Unlike other treatments, KVX-053 works by healing injury, reducing inflammation and restoring lung function.
Partnering listings
Learn more
KeViRx, Inc.
KVX‑053: targeting microvascular leakage and inflammation
What it is: KVX 053 is a first in class, host directed small molecule that stabilizes the endothelial barrier to prevent microvascular leakage, reduce inflammation, and restore lung function/mechanics. It targets PTP4A3...
TechnologyIn developmentCompany
KeViRx, Inc.
Novel small molecule drug KVX-053 for targeting PTP4A3 in asthma and allergy
Introducing KVX-053, a groundbreaking small molecule drug targeting PTP4A3, designed to reduce inflammation and heal lung injury in asthma and allergy patients. Currently in IND-enabling studies, KVX-053 has shown effect...
TechnologyConceptualCompany
Elizabeth Sharlow
CEO
KeViRx, Inc.Work experience
Top industry applications
Pharmaceuticals and drug delivery
Expertise
BiotechnologyPharmacologyTranslational Science
Last updated Jun 2026
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.